$VANI
Vivani Medical, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020053625 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q3
Revenue $472.0K
YoY Change -78.98%
Cost Of Revenue $0.00 $364.0K
YoY Change -100.0% -79.6%
Gross Profit $108.0K
YoY Change -76.62%
Gross Profit Margin 22.88%
Selling, General & Admin $1.320M $1.950M $3.486M
YoY Change -62.13% -50.57% -35.11%
% of Gross Profit 3227.78%
Research & Development $280.0K $320.0K $3.379M
YoY Change -91.71% -90.69% 26.46%
% of Gross Profit 3128.7%
Depreciation & Amortization $20.00K $20.00K $90.00K
YoY Change -77.78% -80.0% -18.18%
% of Gross Profit 83.33%
Operating Expenses $1.600M $2.270M $7.727M
YoY Change -79.29% -74.18% -14.22%
Operating Profit -$1.602M -$3.116M -$7.619M
YoY Change -78.97% -63.08% -10.85%
Interest Expense $20.00K $40.00K
YoY Change 100.0%
% of Operating Profit
Other Income/Expense, Net -$1.000K $35.00K
YoY Change -102.86%
Pretax Income -$1.600M -$3.100M -$7.580M
YoY Change -78.89% -63.27% -11.03%
Income Tax
% Of Pretax Income
Net Earnings -$1.603M -$3.100M -$7.584M
YoY Change -78.86% -63.27% -11.01%
Net Earnings / Revenue -1606.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$69.20K -$152.4K -$486.8K
COMMON SHARES
Basic Shares Outstanding 124.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.440M $3.510M $18.46M
YoY Change -86.78% -86.05% 271.43%
Cash & Equivalents $2.440M $3.505M $18.46M
Short-Term Investments $2.500M
Other Short-Term Assets $870.0K $1.080M $370.0K
YoY Change 135.14% 38.46% -27.45%
Inventory $0.00 $0.00 $1.264M
Prepaid Expenses
Receivables $0.00 $0.00 $264.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.309M $4.581M $20.36M
YoY Change -83.74% -83.67% 98.07%
LONG-TERM ASSETS
Property, Plant & Equipment $193.0K $212.0K $1.125M
YoY Change -82.84% -78.65% 0.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $20.00K $10.00K $20.00K
YoY Change 0.0% -66.67% -33.33%
Other Assets
YoY Change
Total Long-Term Assets $213.0K $224.0K $3.542M
YoY Change -93.99% -93.55% 209.89%
TOTAL ASSETS
Total Short-Term Assets $3.309M $4.581M $20.36M
Total Long-Term Assets $213.0K $224.0K $3.542M
Total Assets $3.522M $4.805M $23.90M
YoY Change -85.26% -84.76% 109.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $285.0K $517.0K $1.126M
YoY Change -74.69% -58.8% -27.17%
Accrued Expenses $1.260M $1.023M $2.082M
YoY Change -39.48% -60.07% 5.42%
Deferred Revenue $335.0K $335.0K $554.0K
YoY Change -39.53% -39.86% 399.1%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.980M $2.722M $7.185M
YoY Change -58.52% -65.27% -4.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $2.430M
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $2.430M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.980M $2.722M $7.185M
Total Long-Term Liabilities $0.00 $0.00 $2.430M
Total Liabilities $2.980M $2.722M $9.612M
YoY Change -69.0% -73.64% 27.65%
SHAREHOLDERS EQUITY
Retained Earnings -$318.4M -$316.8M -$296.9M
YoY Change 7.23% 9.48% 13.93%
Common Stock $270.1M $270.1M $263.7M
YoY Change 2.45% 2.45% 18.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $542.0K $2.083M $14.29M
YoY Change
Total Liabilities & Shareholders Equity $3.522M $4.805M $23.90M
YoY Change -85.26% -84.76% 109.26%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q3
OPERATING ACTIVITIES
Net Income -$1.603M -$3.100M -$7.584M
YoY Change -78.86% -63.27% -11.01%
Depreciation, Depletion And Amortization $20.00K $20.00K $90.00K
YoY Change -77.78% -80.0% -18.18%
Cash From Operating Activities -$1.480M -$5.240M -$6.450M
YoY Change -77.05% -21.08% -13.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$230.0K
YoY Change -100.0% -100.0% 1050.0%
Acquisitions
YoY Change
Other Investing Activities $400.0K
YoY Change
Cash From Investing Activities $400.0K $0.00 -$230.0K
YoY Change -273.91% -100.0% 1050.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 6.410M 0.000
YoY Change 2570.83% -100.0%
NET CHANGE
Cash From Operating Activities -1.480M -5.240M -6.450M
Cash From Investing Activities 400.0K 0.000 -230.0K
Cash From Financing Activities 0.000 6.410M 0.000
Net Change In Cash -1.080M 1.170M -6.680M
YoY Change -83.83% -117.94% 166.14%
FREE CASH FLOW
Cash From Operating Activities -$1.480M -$5.240M -$6.450M
Capital Expenditures $0.00 $0.00 -$230.0K
Free Cash Flow -$1.480M -$5.240M -$6.220M
YoY Change -76.21% -19.63% -16.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Assets
Assets
3522000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
285000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1260000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
393000
CY2020Q3 eyes Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
707000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
237000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
335000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2365000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
472000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
364000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
872000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
3309000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
193000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2342000
CY2020Q3 eyes Deposits And Other Assets
DepositsAndOtherAssets
20000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
270126000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49287000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-498000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318373000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
542000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2980000
CY2020Q3 us-gaap Liabilities
Liabilities
2980000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3522000
CY2020Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23118000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23118000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1602000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
104000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1603000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23118000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
35000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1568000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3084000
CY2019Q1 eyes Stock Issued During Period Value Common Stock And Warrants In Connection With Rights Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
34399000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
898000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9700000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
28529000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34637000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
14000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-9000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
238000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
21195000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
686000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
14286000
CY2020Q1 eyes Repurchase Of Fractional Shares In Connection With Reverse Stock Split
RepurchaseOfFractionalSharesInConnectionWithReverseStockSplit
11000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8886000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1318000
CY2020Q2 eyes Stock Issued During Period Value Common Stock And Warrants In Connection With Rights Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
6673000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
88000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3100000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
10000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
2083000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
293000
us-gaap Share Based Compensation
ShareBasedCompensation
394000
us-gaap Share Based Compensation
ShareBasedCompensation
2443000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3000
us-gaap Operating Lease Expense
OperatingLeaseExpense
13000
us-gaap Inventory Lifo Reserve Effect On Income Net
InventoryLIFOReserveEffectOnIncomeNet
-793000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1116000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
2587000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-461000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-240000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-218000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-186000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
568000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1010000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1256000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-178000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
64000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-282000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2360000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-227000
eyes Increase Decrease Accrued Clinical Trial Expenses
IncreaseDecreaseAccruedClinicalTrialExpenses
-199000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
388000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15369000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20243000
eyes Proceeds From Sale Of Assets Held For Sale
ProceedsFromSaleOfAssetsHeldForSale
398000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
331000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
394000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-394000
eyes Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6679000
eyes Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
34399000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
238000
eyes Repurchase Of Espp Shares And Fractional Shares In Connection With Reverse Stock Split
RepurchaseOfESPPSharesAndFractionalSharesInConnectionWithReverseStockSplit
281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6398000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8890000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13991000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18462000
eyes Fair Value Of Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfWarrantsIssuedInConnectionWithIssuanceOfCommonStock
280000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4778000
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
803000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1477000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1716000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
816000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2069000
CY2020Q3 us-gaap Inventory Gross
InventoryGross
3031000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
4588000
CY2020Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
738000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3400000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6900000
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
600000
CY2019Q3 eyes Grant Received To Develop Spatial Localization And Mapping Technology
GrantReceivedToDevelopSpatialLocalizationAndMappingTechnology
2400000
CY2019Q3 eyes Grant Received Funding Period
GrantReceivedFundingPeriod
P4Y
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8
CY2020Q3 us-gaap Inventory Adjustments
InventoryAdjustments
3031000
CY2019Q4 us-gaap Inventory Adjustments
InventoryAdjustments
3559000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
653000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
460000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3656000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1575000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
618000
eyes Product Warranty Accrual Total
ProductWarrantyAccrualTotal
957000
eyes Finished Goods Inventory Expected To Be Used Or Future Warranty Claims
FinishedGoodsInventoryExpectedToBeUsedOrFutureWarrantyClaims
-236000
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
721000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
117000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
117000
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.10
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
123000
us-gaap Operating Lease Cost
OperatingLeaseCost
229000
us-gaap Operating Lease Cost
OperatingLeaseCost
370000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
48000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
48000
CY2020Q3 us-gaap Lease Cost
LeaseCost
48000
CY2019Q3 us-gaap Lease Cost
LeaseCost
123000
us-gaap Lease Cost
LeaseCost
277000
us-gaap Operating Lease Payments
OperatingLeasePayments
275000
CY2019Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8322000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8985000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
686000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
394000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2443000
CY2020Q3 eyes Number Of Retained Employees
NumberOfRetainedEmployees
12
eyes Date Of Notice Period By Nasdaq
DateOfNoticePeriodByNasdaq
2020-10-01
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
2500000
CY2020Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
500000
CY2020Q3 us-gaap Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net
ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
3000000
CY2020Q3 us-gaap Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net
ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
3000000

Files In Submission

Name View Source Status
0001564590-20-053625-index-headers.html Edgar Link pending
0001564590-20-053625-index.html Edgar Link pending
0001564590-20-053625.txt Edgar Link pending
0001564590-20-053625-xbrl.zip Edgar Link pending
eyes-10q_20200930.htm Edgar Link pending
eyes-20200930.xml Edgar Link completed
eyes-20200930.xsd Edgar Link pending
eyes-20200930_cal.xml Edgar Link unprocessable
eyes-20200930_def.xml Edgar Link unprocessable
eyes-20200930_lab.xml Edgar Link unprocessable
eyes-20200930_pre.xml Edgar Link unprocessable
eyes-ex311_7.htm Edgar Link pending
eyes-ex312_6.htm Edgar Link pending
eyes-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending